Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded to “Strong-Buy” by EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) to a strong-buy rating in a report issued on Monday morning, Zacks.com reports.

A number of other analysts also recently weighed in on the company. Benchmark restated a speculative buy rating and issued a $17.00 target price on shares of Reviva Pharmaceuticals in a research report on Monday, August 26th. Maxim Group reaffirmed a hold rating on shares of Reviva Pharmaceuticals in a report on Friday, August 16th. Finally, HC Wainwright reissued a buy rating and issued a $14.00 price target on shares of Reviva Pharmaceuticals in a research note on Thursday, July 11th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Reviva Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $14.33.

Reviva Pharmaceuticals Trading Up 3.2 %

RVPH opened at $1.28 on Monday. The company has a 50 day moving average of $1.07 and a 200 day moving average of $1.85. Reviva Pharmaceuticals has a 12 month low of $0.60 and a 12 month high of $6.80. The company has a market cap of $38.17 million, a PE ratio of -0.81 and a beta of -0.10.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. Research analysts forecast that Reviva Pharmaceuticals will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Vanguard Group Inc. raised its stake in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,001,836 shares of the company’s stock after buying an additional 26,854 shares during the quarter. Vanguard Group Inc. owned about 3.59% of Reviva Pharmaceuticals worth $3,787,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 63.18% of the stock is currently owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.